Biblio Discovery — Demo Discovery Service

3 results for "Ilan Yanuv"

Showing 1–3 · 0.72 seconds · RSS

  1. Journal Article

    Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

    Meir Schechter; Cheli Melzer-Cohen; Aliza Rozenberg et al.

    Cardiovascular Diabetology, Vol. 20 No. 1 · 2021 · English · DOAJ Scopus

    Abstract Background Randomized controlled trials showed that sodium/glucose cotransporter-2 inhibitors (SGLT2i) protect the heart and kidney in an array of populations with type 2 diabetes (T2D) and increased cardiorenal risk. However, the extent of these benefits also in lower kidney-risk T2D…

  2. Journal Article

    Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults

    Meir Schechter; Cheli Melzer Cohen; Ilan Yanuv et al.

    Cardiovascular Diabetology, Vol. 21 No. 1 · 2022 · English · DOAJ Scopus

    Abstract Background Type-2 diabetes (T2D), chronic kidney disease, and heart failure (HF) share epidemiological and pathophysiological features. Although their prevalence was described, there is limited contemporary, high-resolution, epidemiological data regarding the overlap among them. We aimed…

  3. Journal Article

    Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence

    Meir Schechter; Cheli Melzer Cohen; Alisa Fishkin et al.

    Cardiovascular Diabetology, Vol. 22 No. 1 · 2023 · English · DOAJ Scopus

    Abstract Background In clinical trials enrolling patients with type 2 diabetes (T2D) at high cardiovascular risk, many glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improved albuminuria status and possibly mitigated kidney function loss. However, limited data are available regarding the…